SCHEMBL1905935

SCHEMBL1905935

COc1cc2c(NCc3ccc(C)o3)c(C(N)=O)cnc2cc1-c1c(C)noc1C

nearest known ligand 0.64

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 10/20 0.64
CYP2C9 P11712 10/20 0.64
BRD4 O60885 8/20 0.64
BRD2 P25440 5/20 0.64
BRD3 Q15059 5/20 0.64
CYP2C19 P33261 1/20 0.60
PDE4B Q07343 1/20 0.60
CSF1R P07333 4/20 0.45
MAPK1 P28482 1/20 0.44
LMNA P02545 1/20 0.43
TDP1 Q9NUW8 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18904314 0.87 CYP3A4 (0.70) CYP3A4CYP2C9BRD4BRD2BRD3
SCHEMBL1904764 0.87 BRD4 (0.68) CYP3A4CYP2C9BRD4BRD2BRD3
SCHEMBL1907500 0.85 CYP3A4 (0.68) CYP3A4CYP2C9BRD4BRD2BRD3
SCHEMBL14756281 0.83 CYP3A4 (0.75) CYP3A4CYP2C9BRD4BRD2BRD3
SCHEMBL1905705 0.83 BRD4 (0.63) CYP3A4CYP2C9BRD4BRD2BRD3
SCHEMBL13732062 0.82 BRD4 (0.69) CYP3A4CYP2C9BRD4BRD2BRD3
SCHEMBL15985177 0.78 BRD4 (0.68) CYP3A4CYP2C9BRD4BRD2BRD3
SCHEMBL13731747 0.78 CYP3A4 (0.72) CYP3A4CYP2C9BRD4BRD2BRD3
SCHEMBL1903177 0.78 BRD4 (0.67) CYP3A4CYP2C9BRD4BRD2BRD3
SCHEMBL2725816 0.76 CYP3A4 (0.69) CYP3A4CYP2C9BRD4BRD2BRD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2496576-B1 IMIDAZO[4,5-C]QUINOLINE DERIVATIVES AS BROMODOMAIN INHIBITORS GLAXOSMITHKLINE LLC (US) 2013-12-18 EP disclosed
US-8557984-B2 Imidazo [4, 5-C] quinoline derivatives as bromodomain inhibitors GLAXOSMITHKLINE LLC (US) 2013-10-15 US disclosed
US-8557984-B2 Imidazo [4, 5-C] quinoline derivatives as bromodomain inhibitors GLAXOSMITHKLINE LLC (US) 2013-10-15 US disclosed
US-8557984-B2 Imidazo [4, 5-C] quinoline derivatives as bromodomain inhibitors GLAXOSMITHKLINE LLC (US) 2013-10-15 US disclosed
US-20120232074-A1 Imidazo [4, 5-C] Quinoline Derivatives As Bromodomain Inhibitors GLAXOSMITHKLINE LLC 2012-09-13 US disclosed
US-20120232074-A1 Imidazo [4, 5-C] Quinoline Derivatives As Bromodomain Inhibitors GLAXOSMITHKLINE LLC 2012-09-13 US disclosed
US-20120232074-A1 Imidazo [4, 5-C] Quinoline Derivatives As Bromodomain Inhibitors GLAXOSMITHKLINE LLC 2012-09-13 US disclosed
EP-2496576-A1 IMIDAZO [4, 5-C]QUINOLINE DERIVATES AS BROMODOMAIN INHIBITORS GlaxoSmithKline LLC (US) 2012-09-12 EP disclosed
WO-2011054846-A1 IMIDAZO [4, 5-C] QUINOLINE DERIVATES AS BROMODOMAIN INHIBITORS GLAXOSMITHKLINE LLC (US) 2011-05-12 WO disclosed
WO-2011054846-A1 IMIDAZO [4, 5-C] QUINOLINE DERIVATES AS BROMODOMAIN INHIBITORS GLAXOSMITHKLINE LLC (US) 2011-05-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120232074-A1 Imidazo [4, 5-C] Quinoline Derivatives As Bromodomain Inhibitors BRD4, BRD3, BRPF3 CYP3A4 1579/4885CYP2C9 3411/4885BRD4 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.